Samantha Scollard Truex '92 Th'93 Tu'95

Samantha Truex CEO, Quench Bio, Cambridge, MA

Board Member: Elected 2015

AB Dartmouth College
BE Thayer School of Engineering
MBA Tuck School of Business

Samantha Truex is CEO of Quench Bio, a venture-backed start-up in stealth mode that aims to develop medicines for inflammatory diseases. She is also an entrepreneur-in-residence at Atlas Venture. Sam has more than 20 years of biotech experience, including as COO and Head of Corporate Development for Synlogic where Sam led the strategic process and transaction culminating in the recent reverse merger with Mirna. Prior to Synlogic, Sam was Chief Business Officer for Padlock Therapeutics where she was integral to Padlock's operations and led the process in which Padlock was acquired by Bristol-Myers Squibb. Sam previously spent several years each at Biogen and Genzyme. At Biogen, Sam served as Vice President of Corporate Development, leading negotiations of multiple licensing, collaboration and acquisition transactions and serving as program executive during the launch, preclinical and early clinical phases of medications for hemophilia and MS. At Genzyme, she handled licensing and M&A transactions across multiple business units, including for Genzyme Molecular Oncology and Genzyme Genetics. Earlier in her career, Sam worked for Chiron Diagnostics and Health Advances. In August 2018, Sam became CEO of Quench Bio, a seed-stage venture focused on inhibiting highly inflammatory processes in the innate immune system and funded by Atlas Venture and Arix Bioscience.

In addition to being a member of the Thayer Board, Sam has previously served on the Corporate Collaboration Council advising Thayer's MEM program and on Dartmouth's Alumni Liaison Committee of the Alumni Council.